A Dosing Study of Intravitreal Bevacizumab for Retinopathy of Prematurity
Status:
Completed
Trial end date:
2021-01-28
Target enrollment:
Participant gender:
Summary
The aim of our study was to determine whether a low dose of 0.3125mg intravitreal bevacizumab
is effective in treatment of type 1 ROP as the standard 0.625 mg dose., regarding :
Serum Systemic VEGF levels. Retinal Vascularization.